Company Profile

Duearity AB is a Sweden-based medical technology company. The Company's product is Tinearity G1. Tinearity G1 is a medical device that helps with tinnitus treatment. Tinearity G1 is based on Tinnitus Retraining Therapy, a white noise treatment that has been used clinically for several decades. Tinearity G1 consists of sound elements that lead white noise to the inner ear via the skull bone. The method is non-invasive and the ear canal is not affected.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

06/09/24	Duearity files for bankruptcy	FW
29/08/24	Duearity AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
31/05/24	Duearity AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
11/04/24	Duearity AB Auditor Raises 'Going Concern' Doubt	CI
11/03/24	Duearity Unit Signs US Distribution Deal With Westone Laboratories	MT
10/03/24	Duearity Americas Inc Enters into an Agreement with Westone Laboratories	CI
22/02/24	Duearity AB Reports Earnings Results for the Fourth Quarter and Eight Months Ended December 31, 2023	CI
20/12/23	Duearity AB Reports Sales Results for the Month of December 2023	CI
30/11/23	Duearity AB Reports Earnings Results for the Third Quarter and Five Months Ended September 30, 2023	CI
02/10/23	Duearity AB Signs Distributor Agreement - Covering Belgium, the Netherlands and Luxembourg	CI
25/08/23	Sweden's Duearity Lands Deals for Tinnitus Device in US	MT
25/08/23	Duearity Americas Inc Signs Agreements with the First Clinics in the United States	CI
24/08/23	Duearity AB Reports Earnings Results for the Second Quarter Ended June 30, 2023	CI

10/03/24	Duearity has entered into an agreement with a national distributor in the USA	AQ
06/02/24	Clinics in the US can now purchase Tinearity G1 through a national trading platform	AQ
25/01/24	Tinearity G1 on national TV channel in Portugal	AQ
20/12/23	Duearity's sales SEK 450,000 in December - the best month so far	AQ
02/10/23	Duearity AB has signed a distributor agreement - covering Belgium, the Netherlands and Luxembourg	AQ

Manager	Title	Age	Since
Fredrik Westman CEO	Chief Executive Officer	54	08/06/2020
Johan Larsson DFI	Director of Finance/CFO	-	01/09/2024

Director	Title	Age	Since
Peter Arndt CHM	Chairman	59	01/06/2024
Robert Teklic BRD	Director/Board Member	-	01/06/2024
Johan Larsson BRD	Director/Board Member	-	01/06/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DUEARITY AB	-3.75%	-30.00%	-	-	315K
VEEVA SYSTEMS INC.	+0.36%	+0.67%	-3.49%	+27.56%	43.17B
PRO MEDICUS LIMITED	-0.08%	-0.72%	-45.07%	+133.09%	12.33B
SECTRA AB	+0.41%	+4.63%	-4.43%	+109.86%	5.84B
HEARTFLOW, INC.	-2.44%	+1.21%	+46.94%	-	4.2B
GENERATE BIOMEDICINES, INC.	+1.19%	+1.82%	-	-	2.08B
OMNICELL, INC.	-2.63%	-3.69%	+1.15%	-41.26%	1.49B
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-1.42%	-4.00%	-39.66%	-	1.03B
ARBUTUS BIOPHARMA CORPORATION	-1.36%	-2.32%	+11.70%	+148.04%	1B
SUZHOU MEDICALSYSTEM TECHNOLOGY CO., LTD.	-2.35%	-6.47%	+31.84%	+41.20%	857M
Average	-1.20%	-2.01%	-0.13%	+69.75%	8B
Weighted average by Cap.	+0.01%	-2.21%	-7.65%	+55.57%

Duearity AB Stock

Stocks

DEAR

SE0015949482

Advanced Medical Equipment & Technology

Latest news: Duearity AB

Press Releases: Duearity AB

Quotes and Performance

Managers and Directors: Duearity AB

Medical Software & Technology Services

Company Profile